Conatus pharmaceuticals inc. (CNAT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating activities
Net loss

-10,119

-11,385

-12,562

-13,898

-17,739

-18,010

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-26,084

-

-26,654

-25,854

-25,440

-24,148

-23,440

-23,810

-23,056

-22,319

-22,109

-18,992

-18,563

-15,616

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

53

73

81

78

84

91

99

108

109

108

107

106

105

106

96

87

77

67

67

65

51

38

24

12

11

10

0

0

0

Stock-based compensation expense

4,163

4,153

4,136

3,932

3,700

3,757

3,909

3,947

3,831

4,098

3,946

3,706

3,702

3,354

3,197

3,294

3,396

3,315

3,339

3,189

2,772

2,330

1,721

1,105

615

257

0

0

0

Noncash other financing expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,618

0

0

0

Amortization of premiums and discounts on marketable securities, net

-110

-204

-310

-376

-380

-341

-285

-205

-130

-68

-14

-12

-10

5

51

151

247

328

0

0

0

-

-

-

-

-

-

-

-

Accrued interest included in convertible note payable

-

-

-

-

-

696

749

751

750

658

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquisition of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Share-based compensation in lieu of salaries

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Noncash license expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Changes in operating assets and liabilities:
Collaboration receivables

-3,860

-3,555

-2,459

-1,659

-1,987

310

4,109

-2,147

5,847

867

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid and other current assets

-380

-642

-342

-819

-594

-480

-640

-290

-225

123

367

306

-701

-935

257

317

1,233

1,185

83

-80

-163

251

182

481

603

469

0

0

0

Other assets

-

-

-

-

-

-

-

-

-

872

0

0

0

-

-

-

-

-

-

-

-

62

0

0

0

-

0

0

0

Accounts payable and accrued expenses

-3,887

-2,355

-3,302

-2,974

-7,305

-5,760

-1,842

3,042

8,948

6,638

8,570

6,571

3,476

2,856

75

-560

105

-581

-890

54

-105

1,499

2,356

2,037

1,769

407

0

0

0

Accrued compensation

-684

-1,992

-1,673

-702

-160

222

166

119

157

-343

201

128

49

918

221

114

23

289

157

362

448

-130

900

416

89

961

0

0

0

Deferred revenue

-9,726

-12,890

-16,218

-18,048

-14,373

-15,099

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities, net

-82

-59

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

46

41

38

35

32

29

26

23

20

-60

-90

-126

-165

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-15,892

-20,202

-27,258

-29,530

-33,667

-34,857

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

25,886

-

-24,007

-23,793

-23,496

-22,546

-20,322

-19,504

-19,146

-18,260

-16,713

-15,247

-13,261

-10,631

0

0

0

Maturities of marketable securities

25,842

44,842

53,720

61,260

69,810

69,685

81,055

90,493

91,758

81,877

71,007

48,559

39,716

44,597

48,697

63,267

61,871

62,574

52,142

48,522

55,619

54,072

0

0

0

-

-

-

-

Purchase of marketable securities

11,070

15,494

21,453

30,071

33,844

39,637

46,249

63,954

77,791

121,723

125,098

104,278

90,813

40,905

36,586

40,991

52,394

58,365

50,837

49,537

30,208

29,639

0

0

0

-

-

-

-

Maturities of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Purchase of investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Cash paid to acquire in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Capital expenditures

2

11

62

72

70

66

15

9

28

25

27

23

6

110

0

0

0

-

-

-

-

242

201

71

16

3

0

0

0

Net cash provided by investing activities

14,770

29,337

32,205

31,117

35,896

29,982

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities
Issuance of preferred stock for cash, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of common stock related to initial public offering, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from stock issuances related to exercise of stock options

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-51,103

-

11,919

22,082

9,282

4,119

1,254

-1,193

25,180

24,190

-6,981

-38,924

-48,745

-48,396

0

0

0

Proceeds from issuance of convertible note payable, net

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payment on promissory note

-

-

-

-

-

-

-

-

-

1,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

13,522

0

0

0

-

-

-

-

-

-

-

-

58,608

0

0

0

Issuance of promissory notes and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Distribution to wholly owned subsidiary in connection with spin-off of Idun Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

500

0

0

0

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Proceeds from stock issuances related to exercise of stock options and employee stock purchase plan

-

-

-

-

-

-

-

-

-

169

166

151

162

106

68

68

84

84

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

361

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

22,107

-

11,842

6,240

25,497

22,389

22,301

21,229

-217

-176

-115

59,288

59,652

59,151

0

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

0

140

-

46

2,305

-3,110

44,207

-245

4,529

11,283

3,963

3,233

531

5,817

5,753

-23,810

5,116

-2,354

122

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

-

-

-

-

-

-

-

-

-

5

22

40

57

70

70

70

70

70

70

70

70

70

70

106

88

88

0

0

0

Deferred public offering costs included in accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Conversion of notes payable for preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Conversion of notes payable for common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Issuance of warrants in conjunction with debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

625

0

0

0

Issuance of note payable related to acquisition of in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0